UP TO DATE
LATEST NEWS
Here you'll find the latest posts about our research.
Boehringer Ingelheim and Emfret Analytics sign collaboration and license agreement to advance a first-in-class antibody therapy for acute ischemic stroke
Eibelstadt, Germany – 30.03.2026
Emfret Analytics...
State-of-the-art lecture on GPVI targeting at the GTH Congress 2026 in Bonn, Germany. Emfret´s lead candidate EMA601 underscores its high potential as first-in-class GPVI inhibitor.
Eibelstadt/Würzburg/Bonn...
EMA601: Preclinical development of the humanized anti-GPVI Fab published in the European Heart Journal. A safe lead candidate with unprecedented anti-thrombotic and anti-thrombo-inflammatory potency
Eibelstadt/Würzburg,...
